A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Interleukin-15 (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Admune Therapeutics; Novartis; Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2018.
- 25 Apr 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2018.